Frontiers in Pharmacology has formally retracted a 2022 research article that claimed fisetin attenuated oxidative stress-induced cellular damage in ARPE-19 human retinal pigment epithelial cells. The retraction notice, published on 11 November 2026, states that the data and conclusions of the original study have been deemed unreliable following an investigation into the integrity of the published figures. The original article, titled “Fisetin Attenuated Oxidative Stress-Induced Cellular Damage in ARPE-19 Human Retinal Pigment Epithelial Cells Through Nrf2-Mediated Activation of Heme Oxygenase-1,” was authored by Park C, Noh JS, Jung Y, Leem S-H, Hyun JW, Chang Y-C, Kwon TK, Kim G-Y, Lee H, and Choi YH, and appeared in Volume 13 of the journal in 2022.
The decision to retract the paper was triggered by concerns raised after publication regarding the authenticity of images used in the study’s figures. Specifically, Figure 3E from the retracted article was identified as having been previously published in a different scientific paper. This prior publication was authored by Kang J. S., Choi I. W., Han M. H., and colleagues, and appeared in BMC Complementary and Alternative Medicine in 2015.
Upon discovery of the duplicated image, Frontiers initiated an investigation in accordance with its established policies for handling research integrity concerns. The authors of the original 2022 article were given the opportunity to provide an explanation for the presence of the previously published figure. However, the authors failed to provide a satisfactory explanation during the course of the investigation. As a result, the journal concluded that the reliability of the data and the conclusions drawn in the article could not be maintained, leading to the formal retraction of the work.
The retraction notice was approved by the Chief Executive Editor of Frontiers. It is noted in the official documentation that the authors of the original study do not agree with the decision to retract their article. Despite this disagreement, the journal proceeded with the retraction based on the findings of the integrity investigation. The notice also acknowledges the role of the scientific community in identifying the issue, specifically thanking a user on the platform PubPeer for bringing the published article to the journal’s attention.
The retraction notice was published in Volume 17 of Frontiers in Pharmacology in 2026, under the section of Experimental Pharmacology and Drug Discovery. The notice was received and accepted on 23 October 2026, and published on 11 November 2026. The copyright for the retraction notice is held by the Frontiers Editorial Office, and the article is distributed under the terms of the Creative Commons Attribution License. This license permits the use, distribution, and reproduction of the retraction notice in other forums, provided that the original authors and copyright owners are credited and the original publication is cited.
Subject of Research: Retraction of a 2022 pharmacology study due to image integrity violations
Article Title: Retraction: Fisetin attenuated oxidative stress-induced cellular damage in ARPE-19 human retinal pigment epithelial cells through Nrf2-mediated activation of heme oxygenase-1
Article References: Frontiers Editorial Office (2026). Retraction: Fisetin attenuated oxidative stress-induced cellular damage in ARPE-19 human retinal pigment epithelial cells through Nrf2-mediated activation of heme oxygenase-1. Frontiers in Pharmacology, 17, Article 2038854. https://doi.org/10.3389/fphar.2026.2038854
Image Credits: AI Generated
DOI: 10.3389/fphar.2026.2038854
Keywords: retraction, fisetin, ARPE-19 cells, oxidative stress, Nrf2 pathway, heme oxygenase-1, research integrity, image duplication, Frontiers in Pharmacology, retinal pigment epithelium, scientific misconduct, PubPeer, cellular damage, drug discovery, experimental pharmacology, data reliability, editorial decision, 2022 study, 2026 retraction, BMC Complementary and Alternative Medicine
News Source: Louis Brooks. (November 12, 2026). Frontiers retracts 2022 fisetin study over image integrity concerns. Scienmag.



